- Ergebnisse als:
- Druckansicht
- Endnote (RIS)
- BibTeX
- Tabelle: CSV | HTML
Publikation
Leitbild und Forschungsprofil
Molekulare Signalverarbeitung
Natur- und Wirkstoffchemie
Biochemie pflanzlicher Interaktionen
Stoffwechsel- und Zellbiologie
Unabhängige Nachwuchsgruppen
Program Center MetaCom
Publikationen
Gute Wissenschaftliche Praxis
Forschungsförderung
Netzwerke und Verbundprojekte
Symposien und Kolloquien
Alumni-Forschungsgruppen
Publikationen
Publikation
Using synthetic inhibitors, it has been shown that the ectopeptidase dipeptidyl peptidase IV (DP IV) (CD26) plays an important role in the activation and proliferation of T lymphocytes. The human immunodeficiency virus-1 Tat protein, as well as the N-terminal nonapeptide Tat(1–9) and other peptides containing the N-terminal sequence XXP, also inhibit DP IV and therefore T cell activation. Studying the effect of amino acid exchanges in the N-terminal three positions of the Tat(1–9) sequence, we found that tryptophan in position 2 strongly improves DP IV inhibition. NMR spectroscopy and molecular modeling show that the effect of Trp2-Tat(1–9) could not be explained by significant alterations in the backbone structure and suggest that tryptophan enters favorable interactions with DP IV. Data base searches revealed the thromboxane A2 receptor (TXA2-R) as a membrane protein extracellularly exposing N-terminal MWP. TXA2-R is expressed within the immune system on antigen-presenting cells, namely monocytes. The N-terminal nonapeptide of TXA2-R, TXA2-R(1–9), inhibits DP IV and DNA synthesis and IL-2 production of tetanus toxoid-stimulated peripheral blood mononuclear cells. Moreover, TXA2-R(1–9) induces the production of the immunosuppressive cytokine transforming growth factor-β1. These data suggest that the N-terminal part of TXA2-R is an endogenous inhibitory ligand of DP IV and may modulate T cell activation via DP IV/CD26 inhibition.